The GSK name and elements of the incumbent orange logo have been retained in the new identity. Stevens says that the decision to retain the orange was partly driven by the fact that “the world of ...

GSK’s departure comes as the industry anticipates the incoming Trump administration and as it continues to grapple with the threat of the BIOSECURE Act and losses of legal challenges to the IRA’s drug ...

GlaxoSmithKline is under pressure from shareholders ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...

Questions remain about GSK’s ability to come up with new drugs and litigation over the antacid Zantac, and the stock still ...

Investors in GSK plc (Symbol: GSK) saw new options begin trading today, for the May 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time ...

limited upside in pipeline catalysts and 2025 estimates “makes it increasingly challenging for us to recommend that investors put new money to work in GSK until pipeline visibility improves ...

GSK plc GSK announced that the FDA has accepted ... Shingrix and meningitis portfolio and exceptional contribution from the new respiratory syncytial virus (RSV) vaccine, Arexvy.

GSK (GSK.L), opens new tab has agreed to pay up to $2.2 billion to settle most lawsuits in U.S. state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer ...

Drugmaker GSK shared positive results Monday from two Phase 3 trials testing its inflammatory disease drug depemokimab in people with a condition known as chronic rhinosinusitis with nasal polyps.

GSK Cars: Your Premier Destination for Quality Vehicles At GSK Cars, we pride ourselves on offering an extensive selection of high-quality vehicles to suit every need and budget. Located conveniently ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...